Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Arginine Metabolism in Youth With Type 2 Diabetes

NCT05477134
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

NCT06033209
View directory record Official record
Conditions
HIV
Interventions
N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus), N332-GT5 gp140 (SC, Fractioned), SMNP (IM, Bolus), SMNP (IM, Fractioned), SMNP (SC, Bolus), SMNP (SC, Fractioned)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
8
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions
Hiltonol
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

NCT04715022
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Ascorbic acid solution (American Regent Laboratories Inc.), Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Not applicable Interventional Results available

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

NCT06728059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Not applicable Interventional

Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology

NCT06955468
View directory record Official record
Conditions
Lung Cancers, Gastrointestinal Cancers
Interventions
Priming Survey
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

NCT03409276
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Cannabis' Impact on Alcohol Consumption

NCT05389930
View directory record Official record
Conditions
Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions
THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 50 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

NCT00616564
View directory record Official record
Conditions
Malignant Melanoma
Interventions
GM-CSF
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
16 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Miami Beach, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 25, 2026, 10:56 AM EDT
Completed No phase listed Observational

COVID-19 Antibody Levels After Vaccines

NCT04944134
View directory record Official record
Conditions
Vaccine Preventable Disease
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
71 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

NCT02827500
View directory record Official record
Conditions
Heart Failure
Interventions
ivabradine, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Aurora, Colorado • Fort Lauderdale, Florida • Athens, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 25, 2026, 10:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Brain Function During Cognitive Tasks

NCT00076739
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years to 40 Years
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

NCT06843434
View directory record Official record
Conditions
Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma
Interventions
Balstilimab, Botensilimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Not applicable Interventional Results available

Effect of Behavioral Nudges on Serious Illness Conversation Documentation

NCT04867850
View directory record Official record
Conditions
Cancer
Interventions
Usual Care, Clinician Nudge, Patient Nudge
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
4,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 25, 2026, 10:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Physical Resilience: Indicators and Mechanisms in the Elderly (PRIME) Collaborative Phase 2

NCT04235309
View directory record Official record
Conditions
Resilience, Aging
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 25, 2026, 10:56 AM EDT
Active, not recruiting Phase 1 Interventional

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752
View directory record Official record
Conditions
Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Interventions
Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

NCT01181986
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
Drug
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 25, 2026, 10:56 AM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Not applicable Interventional Results available

PRIME Care (PRecision Medicine In MEntal Health Care)

NCT03170362
View directory record Official record
Conditions
Major Depression
Interventions
Pharmacogenetic Test
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
1,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
North Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Cortical Priming

NCT07860073
View directory record Official record
Conditions
Stroke, Hemiparesis After Stroke
Interventions
5 Hz Repetitive transcranial magnetic stimulation (rTMS) on the contralesional dorsal premotor cortex (cPMd), 5 Hz Repetitive transcranial magnetic stimulation (rTMS) on the ipsilesional primary motor cortex (iM1)
Device
Lead sponsor
Wan-Wen Liao
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Not applicable Interventional

PRIME vs Usual Care for Clinical High Risk

NCT02960451
View directory record Official record
Conditions
Clinical High Risk Syndrome for Psychosis
Interventions
PRIME care, Usual care
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 25, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

NCT00561002
View directory record Official record
Conditions
Influenza
Interventions
2007-2008 Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 25, 2026, 10:56 AM EDT